NL
DE
Because of the low prevalence, not much is known about the natural history of patients with congenital disorders of glycosylation (CDG). Knowledge about the natural disease course is of major importance to inform patients and parents and to prepare intervention studies. The CDG Biobank contains biomaterial (DNA, plasma (EDTA and heparin) and urine) and specific data from the medical file of participating patients.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
New template available for participant information and informed consent
21 October 2025The new Radboud Biobank template Participant Information Form (PIF) and Informed Consent (IC) for biobank collections is based on the standard developed within the NFU Mutual Recognition project.
go to page
Radboudumc Researchers Highlight Critical Gaps in Reporting Pre-Analytical Processes in Biobanked Biomaterials
21 October 2025Radboudumc Researchers have identified significant shortcomings in pre-analytical sample processing reporting in clinical biomarker research, a factor crucial for study reliability and replicability.
go to page
The National Biobanks & Collections Day
21 October 2025On Thursday, March 19, 2026, the third edition of the National Biobanks & Collections Day will be organized in Utrecht at the Princess Máxima Center for Pediatric Oncology.
go to page
First implications of the Radboud Biobank new business model
15 July 2025It was communicated in an earlier news item that the Radboudumc Board of Directors decided to change the Radboud Biobank business model.
go to page
Relocation of Radboud Biobank samples to Central Freezing Facility
15 July 2025The Radboud Biobank has now transferred almost all stored samples to the central freezing facility.
go to pageStandardized Radboud Biobank procedures for sample handling in Elabgids
15 July 2025The Radboud Biobank is currently preparing to include all standardized Radboud Biobank procedures for sample handling in the eLabgids.
go to page